Nasal Human Abuse Potential of PTI-821

NCT03475862 PHASE1 COMPLETED

The study will evaluate the human abuse liability of PTI-821 (oxycodone extended-release capsules) when administered nasally compared to crushed oxycodone IR tablets and crushed OxyContin tablets, also administered nasally.

Details

Lead sponsor	Pain Therapeutics
Phase	PHASE1
Status	COMPLETED
Enrolment	38
Start date	Mon May 15 2017 00:00:00 GMT+0000 (Coordinated Universal Time)
Completion	Fri Dec 15 2017 00:00:00 GMT+0000 (Coordinated Universal Time)

Conditions

• Opioid Abuse Nondependent

Interventions

• PTI-821 capsule Manipulated
• PTI-821 Non-manipulated
• OxyContin
• Placebo
• Oxycodone

Countries

United States